Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863 on ClinicalTrials.gov · last registry update 2026-04-30
Recruiting now, toward 60 participants. Due to report 30 March 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: heart rate variability（HRV）. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2026-04-01
- Primary completion
- 2028-03-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
heart rate variability（HRV）
Conditions studied
Type 2 Diabetes · Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.